Elmind Capital LP Has $9.52 Million Stake in BioCryst Pharmaceuticals, Inc. $BCRX

Elmind Capital LP lowered its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 53.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,000,000 shares of the biotechnology company’s stock after selling 1,150,000 shares during the quarter. BioCryst Pharmaceuticals makes up approximately 2.7% of Elmind Capital LP’s investment portfolio, making the stock its 13th largest position. Elmind Capital LP’s holdings in BioCryst Pharmaceuticals were worth $9,520,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. Royal Bank of Canada grew its holdings in shares of BioCryst Pharmaceuticals by 2.4% during the 1st quarter. Royal Bank of Canada now owns 63,463 shares of the biotechnology company’s stock valued at $476,000 after purchasing an additional 1,458 shares during the last quarter. Cetera Investment Advisers boosted its position in BioCryst Pharmaceuticals by 13.8% in the fourth quarter. Cetera Investment Advisers now owns 12,330 shares of the biotechnology company’s stock valued at $96,000 after buying an additional 1,494 shares in the last quarter. Captrust Financial Advisors grew its stake in shares of BioCryst Pharmaceuticals by 7.4% during the second quarter. Captrust Financial Advisors now owns 22,105 shares of the biotechnology company’s stock worth $198,000 after buying an additional 1,527 shares during the last quarter. Counterweight Ventures LLC grew its stake in shares of BioCryst Pharmaceuticals by 2.1% during the fourth quarter. Counterweight Ventures LLC now owns 95,384 shares of the biotechnology company’s stock worth $744,000 after buying an additional 2,000 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of BioCryst Pharmaceuticals by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after buying an additional 2,115 shares in the last quarter. 85.88% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and issued a $32.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, June 30th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of BioCryst Pharmaceuticals in a report on Monday, June 1st. Royal Bank Of Canada increased their target price on BioCryst Pharmaceuticals from $13.00 to $14.00 and gave the company an “outperform” rating in a research report on Tuesday, July 7th. Wall Street Zen lowered BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Saturday, May 9th. Finally, Needham & Company LLC reduced their price target on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating on the stock in a report on Wednesday, May 6th. Eight analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $20.80.

BioCryst Pharmaceuticals Stock Performance

BCRX stock opened at $9.58 on Tuesday. The company has a fifty day moving average price of $9.23 and a 200-day moving average price of $8.59. The company has a market capitalization of $2.43 billion, a P/E ratio of -5.38 and a beta of 0.55. BioCryst Pharmaceuticals, Inc. has a 52-week low of $6.00 and a 52-week high of $11.22.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share for the quarter, missing the consensus estimate of $0.06 by ($3.04). The business had revenue of $156.41 million during the quarter, compared to the consensus estimate of $151.12 million. BioCryst Pharmaceuticals had a negative return on equity of 76.36% and a negative net margin of 51.71%.The business’s revenue for the quarter was up 7.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.20 EPS. As a group, sell-side analysts forecast that BioCryst Pharmaceuticals, Inc. will post -2.58 earnings per share for the current fiscal year.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.